Erratum: Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: Open-label continuation study (Allergy and Asthma Proceedings (2013) 34 (155-161) DOI: 10.2500/aap.2013.34.3653);Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: Open-label continuation study

Allergy and Asthma Proceedings

Volumn 34, Issue 2, 2013, Pages 155-161

  Lumry, William R ^a   Bernstein, Jonathan A ^b   Li, H Henry ^c   MacGinnitie, Andrew J ^d   Riedl, Marc ^e   Soteres, Daniel F ^f   Craig, Timothy J ^g   Campion, Marilyn ^h   Iarrobino, Ryan ⁱ   Stolz, Leslie E ⁱ   Pullman, William E ⁱ  

^a Allergy and Asthma Specialists   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c Institute for Asthma and Allergy   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Asthma and Allergy Associates and Research Center   (United States)

^g PENN STATE COLLEGE OF MEDICINE   (United States)

^h Independent Consulting Services   (United States)

ⁱ Dyax Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECALLANTIDE; PLACEBO;

ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; CHILD; CONFUSION; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ERYTHEMA; FEMALE; FOLLOW UP; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; PRURITUS; RECURRENT DISEASE; SCHOOL CHILD; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 84876003802     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2013.34.3662     Document Type: Erratum

References (17)

1. Bork K, Meng G, Staubach P, and Hardt J. Hereditary angioedema: New findings concerning symptoms, affected organs, and course. Am J Med 119:267-274, 2006. (Pubitemid 43255068)
2. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: Consensus document. Clin Exp Immunol 139:379-394, 2005. (Pubitemid 40333248)
3. Khan DA. Hereditary angioedema: Historical aspects, classification, pathophysiology, clinical presentation, and laboratory diagnosis. Allergy Asthma Proc 32:1-10, 2011.
4. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 359:1027-1036, 2008.
5. CSL Behring, LLC. Berinert, C1 esterase inhibitor (human) package insert. Kankakee, IL; December, 2011.
6. Dyax Corp. Kalbitor (ecallantide) package insert. Burlington, MA; February, 2012.
7. Shire Orphan Therapies. Firazyr (icatibant) package insert. Lexington, MA; August, 2011.
8. Cugno M, Zanichelli A, Foieni F, et al. C1-inhibitor deficiency and angioedema: Molecular mechanisms and clinical progress. Trends Mol Med 15:69-78, 2009.
9. Levy JH, and O'Donnell PS. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin Investig Drugs 15:1077-1090, 2006. (Pubitemid 44314659)
10. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 363:523-531, 2010.
11. Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: A phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 104:523-529, 2010.
12. Vernon MK, Rentz AM, Wyrwich KW, et al. Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema. Qual Life Res 18:929-939, 2009.
13. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: Summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 117:391-397, 2006. (Pubitemid 43190153)
14. MacGinnitie AJ, Campion M, Stolz LE, and Pullman WE. Ecallantide for treatment of acute hereditary angioedema attacks: Analysis of efficacy by patient characteristics. Allergy Asthma Proc 33:178-185, 2012.
15. Lunn M, and Banta E. Ecallantide for the treatment of hereditary angioedema in adults. Clin Med Insights Cardiol 5:49-54, 2011.
16. Craig TJ, Bewtra AK, Bahna SL, et al. C1 esterase inhibitor concentrate in 1085 hereditary angioedema attacks-Final results of the I.M.P.A.C.T. 2 study. Allergy 66:1604-1611, 2011.
17. Bork K, and Hardt J. Hereditary angioedema: Long-term treatment with one or more injections of C1 inhibitor concentrate per week. Int Arch Allergy Immunol 154:81-88, 2011.